Company intelligence / Profile preview

BioSpero, Inc.

Jeju-si, Jeju, South Koreabiospero.com ↗

Ownership: Private
Development stage: Preclinical

Overview

BioSpero has validated its microphysiological systems through collaborations with research hospitals and universities. The company’s platforms enable highly predictive in vitro assessments of drug toxicity and efficacy by emulating complex human organ functions on microfluidic chips. This approach aims to improve translational accuracy over traditional animal models. No clinical trial results reported as the company provides enabling technology rather than therapeutics.

Therapeutic areas: NephrologyOncologyOtherGastroenterologyNeurology
Modalities: Organ-on-Chip systemsMicrophysiological Systems (MPS)
Industry: Drug Discovery Services

Partnerships

Collaborations with research hospitals, institutes, universitiesseeking strategic partners for platform adoption and co-development

Beyond the preview

Go deeper on BioSpero, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSpero, Inc..

Explore the full profile